SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

OPK RSS Feed
Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/15/2017 4:25:12 PM - Followers: 162 - Board type: Free - Posts Today: 0

Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
SureTrader
Interactive Brokers Advertisement
OPK
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OPK News: OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy 11/27/2017 11:02:41 AM
OPK News: Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update 11/15/2017 07:05:00 AM
OPK News: Current Report Filing (8-k) 11/13/2017 04:03:06 PM
OPK News: Current Report Filing (8-k) 11/08/2017 04:40:07 PM
OPK News: Quarterly Report (10-q) 11/08/2017 04:29:05 PM
PostSubject
#5806   Yes I hope there is something behind it Very odd Juice555 12/15/17 04:25:12 PM
#5805   Yea. pushing 3 months without a buy. why game7alcs 12/15/17 04:19:37 PM
#5804   Don't forget how much the market has risen terry hallinan 12/14/17 11:07:47 AM
#5803   I am not buying but selling.....unfortunately this is now invest 12/14/17 08:26:44 AM
#5802   And if I am way, way off the terry hallinan 12/11/17 10:18:05 AM
#5801   Thanks Terry game7alcs 12/10/17 06:42:27 PM
#5800   OPKO Health: A House Of Cards Tumbling In terry hallinan 12/10/17 06:05:43 PM
#5799   You too game7alcs 12/09/17 02:41:10 PM
#5798   You are right... Let's see what happens... Have a nice weekend Juice555 12/09/17 02:40:34 PM
#5797   Yea hopefully. I know it's old but the game7alcs 12/09/17 02:38:36 PM
#5796   This article is old and I think already Juice555 12/09/17 02:36:14 PM
#5795   Ouch! game7alcs 12/09/17 12:06:22 PM
#5794   are you saying this is really Dr. Frost's terry hallinan 12/05/17 10:40:04 AM
#5793   I will say this. You have some interesting game7alcs 12/05/17 10:22:58 AM
#5792   Who knows though. terry hallinan 12/04/17 11:08:28 AM
#5791   I hope you're right. I just think it's game7alcs 12/01/17 08:17:03 PM
#5790   He has been buying even in the teens I Juice555 12/01/17 08:13:39 PM
#5789   I wonder if he just decided to stop game7alcs 12/01/17 08:09:49 PM
#5788   Another week and no buys from Frost or Juice555 12/01/17 07:55:51 PM
#5787   As I review the advancement of Opko (Dr. tredenwater2 11/30/17 09:44:48 PM
#5786   www.medicalnewstoday.com/articles/319963.php Good news Sky10 11/30/17 03:08:53 PM
#5785   Still haven't seen it!!!! You would now invest 11/29/17 06:26:04 AM
#5784   Hey good news we will find out the game7alcs 11/27/17 08:36:19 PM
#5783   MSNBC? No wonder it was so cheap. You game7alcs 11/27/17 07:06:39 PM
#5782   I do not know , I got this Sky10 11/27/17 01:26:54 PM
#5781   I distinctly remember that cc and agree that game7alcs 11/25/17 03:32:16 PM
#5780   Your welcome game. If Dr. Frost wasnt so tredenwater2 11/25/17 03:26:52 PM
#5779   Tred has some good thoughts on this. game7alcs 11/25/17 12:26:25 PM
#5778   All good thoughts. Thanks for the response. game7alcs 11/25/17 12:25:28 PM
#5777   I also find it odd that he is Juice555 11/25/17 12:23:23 PM
#5776   Game not sure why because he has bought tredenwater2 11/25/17 11:17:30 AM
#5775   A short question to a detailed post. If game7alcs 11/25/17 08:59:26 AM
#5774   I was recently reviewing the letter Dr. Frost tredenwater2 11/25/17 12:07:18 AM
#5773   What time was it on?? Did you now invest 11/22/17 08:18:54 PM
#5772   Ad 4 kscores was on MSNBC tv Long Sky10 11/22/17 05:50:02 PM
#5771   I haven't seen one I was looking online game7alcs 11/22/17 02:47:34 PM
#5770   Anyone see a 4k Commercial yet?? now invest 11/22/17 10:31:59 AM
#5769   The way things work in the world today. game7alcs 11/21/17 12:35:43 PM
#5768   Ah... OPK starting add for 4k... and now invest 11/21/17 11:23:05 AM
#5767   Thanks for your thoughts Terry. Nice perspective. tredenwater2 11/19/17 08:29:39 AM
#5766   I also agree with Game7alcs that one can terry hallinan 11/18/17 09:16:57 PM
#5765   Question for the board. Did Opko "outlicense" tredenwater2 11/18/17 02:26:38 PM
#5764   Got it Thanks I got a "gut" feeling something is Juice555 11/17/17 05:36:17 PM
#5763   Sorry Juice, I meant according to Cramer. He uses game7alcs 11/17/17 04:58:49 PM
#5762   That doesn't mean anything.... The stock will probably D theG 11/17/17 08:35:58 AM
#5761   Sorry what does that mean What am I missing Thanks Juice555 11/16/17 08:30:29 PM
#5760   OPKO is in the neighborhood of pain acceding game7alcs 11/16/17 08:04:34 PM
#5759   The point is... THAT AFTER ALL THESE YEARS... now invest 11/16/17 01:35:32 PM
#5758   "The company is still working off substantial debts tredenwater2 11/16/17 11:08:15 AM
#5757   My options are in jan 2019 lets see rarefind 11/16/17 10:24:03 AM
PostSubject